Related Experiment Video
Updated: May 27, 2026
07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Molecular pathways associated with mortality in papillary thyroid cancer
Naris Nilubol1, Chotiya Sukchotrat, Lisa Zhang
1Endocrine Oncology Section, Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA. niluboln@mail.nih.gov
Surgery
|December 6, 2011
Summary
This study used genome-wide expression analysis to identify molecular pathways linked to poor outcomes in papillary thyroid cancer (PTC). A 100-gene signature effectively distinguished patients based on mortality risk.
Area of Science:
- Genomics
- Molecular Biology
- Oncology
Background:
- Understanding molecular drivers of papillary thyroid cancer (PTC) is crucial for effective patient management.
- Identifying molecular pathways associated with unfavorable outcomes in PTC is a key clinical need.
Purpose of the Study:
- To identify molecular pathways linked to unfavorable features and outcomes in papillary thyroid cancer (PTC).
- To investigate genome-wide expression patterns associated with PTC-related mortality.
Main Methods:
- Genome-wide expression (GWE) analysis was performed on 64 human PTC tissue samples.
- Gene set enrichment analysis (GSEA) identified molecular pathways associated with mortality.
- Clinical, pathologic, and microarray data were analyzed for differential gene expression.
Main Results:
- GWE analysis identified significant differential gene expression related to gender, tumor differentiation, and mortality.
- GSEA revealed 7 enriched pathways associated with mortality, including tRNA synthesis and oxidative phosphorylation.
- A 100-gene signature demonstrated complete separation of patients based on mortality.
Conclusions:
- This is the first GWE analysis of PTC and adverse outcomes.
- Eleven molecular pathways were significantly associated with PTC-related mortality.
- A 100-gene signature accurately predicts PTC-associated mortality.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...